CN106581870A - Purpose of light-message-transmission-medium energy enablement lamp serving as treatment device for myocardial ischemia - Google Patents
Purpose of light-message-transmission-medium energy enablement lamp serving as treatment device for myocardial ischemia Download PDFInfo
- Publication number
- CN106581870A CN106581870A CN201710124505.2A CN201710124505A CN106581870A CN 106581870 A CN106581870 A CN 106581870A CN 201710124505 A CN201710124505 A CN 201710124505A CN 106581870 A CN106581870 A CN 106581870A
- Authority
- CN
- China
- Prior art keywords
- myocardial ischemia
- cabinet
- metal alloy
- panel
- carbon pipe
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000031225 myocardial ischemia Diseases 0.000 title claims abstract description 34
- 230000000694 effects Effects 0.000 claims abstract description 10
- 230000002265 prevention Effects 0.000 claims abstract description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- 229910052799 carbon Inorganic materials 0.000 claims description 13
- 229910001092 metal group alloy Inorganic materials 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- 238000001228 spectrum Methods 0.000 claims description 6
- 239000000779 smoke Substances 0.000 claims description 5
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 claims description 3
- 239000004033 plastic Substances 0.000 claims description 3
- 229920003023 plastic Polymers 0.000 claims description 3
- 238000010521 absorption reaction Methods 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 230000009286 beneficial effect Effects 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 230000005855 radiation Effects 0.000 claims description 2
- 150000001450 anions Chemical class 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 3
- 241000700159 Rattus Species 0.000 description 30
- 230000037396 body weight Effects 0.000 description 11
- JLTCWSBVQSZVLT-CDIPANDDSA-N (2s)-n-[(2s)-6-amino-1-[(2-amino-2-oxoethyl)amino]-1-oxohexan-2-yl]-1-[(4r,7s,10s,13s,16s,19r)-19-amino-7-(2-amino-2-oxoethyl)-10-(3-amino-3-oxopropyl)-13-benzyl-16-[(4-hydroxyphenyl)methyl]-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosan Chemical compound NCCCC[C@@H](C(=O)NCC(N)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]1NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](N)CSSC1.C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 JLTCWSBVQSZVLT-CDIPANDDSA-N 0.000 description 10
- 102000005320 Posterior Pituitary Hormones Human genes 0.000 description 10
- 108010070873 Posterior Pituitary Hormones Proteins 0.000 description 10
- 230000000302 ischemic effect Effects 0.000 description 8
- 210000004165 myocardium Anatomy 0.000 description 8
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 238000011084 recovery Methods 0.000 description 5
- 239000000047 product Substances 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 208000029078 coronary artery disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 241000256856 Vespidae Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000013475 authorization Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000005693 optoelectronics Effects 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 201000000057 Coronary Stenosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 206010000891 acute myocardial infarction Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008081 blood perfusion Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000037149 energy metabolism Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 208000037891 myocardial injury Diseases 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
- A61M11/005—Sprayers or atomisers specially adapted for therapeutic purposes using ultrasonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
- A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
- A61M2205/052—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0632—Constructional aspects of the apparatus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/065—Light sources therefor
- A61N2005/0655—Tubes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0659—Radiation therapy using light characterised by the wavelength of light used infrared
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0658—Radiation therapy using light characterised by the wavelength of light used
- A61N2005/0662—Visible light
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/06—Radiation therapy using light
- A61N2005/0664—Details
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Radiology & Medical Imaging (AREA)
- Pathology (AREA)
- Anesthesiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention discloses a purpose of a light-message-transmission-medium energy enablement lamp in preparing a device for preventing and/or treating myocardial ischemia. The light-message-transmission-medium energy enablement lamp has an exact treatment and myocardial ischemia prevention effect, provides a new selection for treatment of clinical cardiovascular diseases and has a wide clinical application and market prospect.
Description
Technical field
The present invention relates to a kind of device for treating myocardial ischemia.
Background technology
Myocardial ischemia refers to that the blood perfusion of heart is reduced, and the oxygen supply for causing heart is reduced, and energy metabolism of myocardial is abnormal,
A kind of disease of normal heart action can not be supported.Coronary stenosis or obturation are to cause cardiac muscle caused by coronary atherosclerosis
Ischemic is main, the modal cause of disease, and then causes myocardial ischemia-anoxemia, i.e., " coronary heart disease ".In coronary heart disease, in ischemic
Wind, acute myocardial infarction, Buerger's disease, diabetes and wound etc. make erythrocyte aggregation increase and make WBV
Raise.
At present, drug therapy is one of common treatment method of myocardial ischemia disease.
Existing document report shows that infrared ray combined atomizing treatment method has uniqueness in the treatment of angiocardiopathy
Advantage.Compare with drug therapy, physical treatment incorporates the good effect of Chinese medicine, activity is strong, the features such as toxic and side effect is few, increasingly
By the concern and application of vast cardiovascular patient.
The content of the invention
In order to solve the above problems, the invention provides a kind of device of new treatment myocardial ischemia.
The invention provides open can purposes of the lamp in the device for preparing prevention and/or treating myocardial ischemia.
Wherein, described device is the device for preventing and/or treating acute myocardial ischemia.
Wherein, described device is to shorten the device of duration of myocardial ischemia.
Wherein, the energy lamp that opens includes that superoxide anion O can be produced2 -Broad band full spectrum frequency spectrograph and ultrasonic humidifying
Device；The broad band full spectrum frequency spectrograph from top to bottom includes cabinet, support and the base of earth-free outer shielding structure；The modeling
Metal alloy plate, quartzy carbon pipe are provided with material casing；The quartzy carbon pipe is used to radiate having for 500nm～2.5 μm frequency spectrum
Beneficial visible ray and near, mid-infrared light；The metal alloy plate absorbs infrared from 500nm～2.5 mum wavelength of quartzy carbon pipe,
It is infrared that 2.5 μm～25 mum wavelengths are radiated simultaneously；The support is used for supporting plastic casing and connection cabinet and base；It is described
Metal alloy plate top is composed in series by least 10 quartzy carbon pipes；The ultrasonic humidifier is located at broad band full and composes frequency spectrograph
It is used to produce a large amount of water smokes and human body between, the light quantum generation effect that water smoke need to send with frequency spectrograph, water smoke is in frequency spectrograph face
The optimum distance disappeared before plate for ultrasonic humidifier and frequency spectrograph.
Preferably, the front of the cabinet is provided with machine shell panel, and machine shell panel is provided with panel guard；The plastics
Micro- shape fan, metal air chamber, metal alloy plate, quartzy carbon pipe are respectively equipped with casing by rear to front；The cabinet it is upper,
Under be respectively provided with double louvres, this pair of louvre is used to guaranteeing that extraneous air is entered under the twitch of micro- shape fan being fixed on cabinet
On metal air chamber；Metal air chamber surrounding lower section is equipped with air admission hole, for guaranteeing air via 2.5 μm～25 mum wavelengths of radiation
Infrared metal alloy plate surface space electronic cloud, absorption negative electrical charge forms superoxide anion, and Jing panel guards are communicated to air
In.
It is further preferred that the metal alloy plate top is composed in series by least 10 quartzy carbon pipes；The casing
Panel is provided with power switch and quartzy carbon pipe switch；Automatic line receiver, spooler jump ring are set in the base, and is used for
The anti-dumping switch automatically powered off when base inclines more than 15 degree of angles.
It is of the present invention to open energy lamp, energy lamp is opened also known as light news, purchased from Shanghai Qiangli Optoelectronic Technology Co., Ltd., product type
Number：GXZ5A, product standard：Q/SWLB 01-2014, its structure is recorded in the patent that Authorization Notice No. is the B of CN 102451524
In application, specifically, is seen【0022】~【0040】It is shown.
The present invention opens energy light fixture definite treatment and prevention myocardial ischemia, is the treatment of clinical cardiovascular disease
There is provided a kind of new selection, with wide clinical practice and market prospects.
Obviously, the above of the invention, according to the ordinary technical knowledge and customary means of this area, without departing from
Under the premise of the above-mentioned basic fundamental thought of the present invention, the modification of other various ways can also be made, is replaced or is changed.
By the following examples the specific embodiment of form, remakes further specifically to the above of the present invention
It is bright.But this scope for being interpreted as above-mentioned theme of the invention should not be only limitted to Examples below.It is all based on the above of the present invention
The technology realized belongs to the scope of the present invention.
Description of the drawings
Fig. 1 is opened can impact of the lamp to rats with myocardial ischemia body weight.Note：7th day rat body weight, compares with control group, * P ＜
0.05。
Fig. 2 opens energy lamp to the Electrocardiographic impact of rats with myocardial ischemia.(A) Electrocardiographic situation of change before and after rat ischemia；
(B) after pituitrin injection, there is the time of ischemic and recovery in rat.Note：Compare with control group, * P ＜ 0.05；With compare
Group compares ， ＆P ＜ 0.05.
Specific embodiment
The present invention of embodiment 1 treats myocardial ischemia using energy lamp is opened
1 material
1.1 animal used as test
From SPF levels Spahue-Dawlay (SD) rat, male, 160 ± 5g of body weight, by Shanghai Si Laike animals used as test
Center provides (credit number：SCXK (Shanghai) 2007-0005).Put Fujian University of Traditional Chinese Medicine's Experimental Animal Center SPF level laboratory
In normally feed, constant temperature, constant humidity, 12h illumination/day, adaptability feed 1 week after, carry out follow-up test.
1.2 Experimental agents and main agents
Pituitrin parenteral solution (the second hormone of Ningbo of Zhejiang factory)；(Solution on Chemical Reagents in Shanghai import is public for yellow Jackets
Department)；Heparin sodium injection (Jiangsu Wanbang Biological Pharmaceutical Co., Ltd.).
1.3 experiment key instruments
Energy lamp is opened, also known as light news energy lamp, purchased from Shanghai Qiangli Optoelectronic Technology Co., Ltd., its model product type are opened
Number：GXZ5A, product standard：Q/SWLB 01-2014, its structure is recorded in the patent that Authorization Notice No. is the B of CN 102451524
In application, specifically, is seen【0022】~【0040】It is shown.
Electronic balance scale (Shanghai Ao Haosi Instrument Ltd.)；Biological functional system BL-420S (Chengdu Tai Meng sections
Skill Co., Ltd)；LBY-N6B Full-automatic self-cleaning blood rheological instruments (Pulisheng Instruments Co., Ltd., Beijing).
2 experimental techniques
2.1 rats are grouped
Healthy SPF levels SD male rat 20,160 ± 5g of body weight is placed in SPF levels laboratory and raises, freely activity, from
By feed, drinking-water, ventilation, illumination is sufficient, and room temperature is controlled in (25 ± 1) DEG C, relative humidity 70%-80%.Adaptability is raised 3 days
After tested.2 groups, i.e. control group are randomly divided into using random digits table by body weight, intervention group (opens energy lamp treatment group), often
Group 10.
2.2 open can light irradiation method
After energy lamp and atomizer preheating 10min will be opened before intervention, device to be atomized has uniform water smoke ejection to be preferred, and rat is put
In the carton of surrounding perforate ventilation, and supplements and water, adjustment lampshade is highly 30cm, intervenes 30min, once a day,
It is continuous to intervene 7 days.
The weighing of 2.3 rat body weights
Rat is grouped at random by body weight, after the 1st intervention is carried out to intervention group, the body before intervening every other day to rat
Weighed again again, i.e., weighed and recorded rat body weight within the 1st, 3,5 and the 7th days.
The foundation of 2.4 Model Rats with Acute Myocardial Ischemia
The yellow Jackets (40mg/ml) of 7th the Heavenly Stems prognosis 1h lumbar injections 1% anaesthetize, treat rat lie down, human body it is soft,
After showing anesthesia success, rats by intraperitoneal injection pituitrin (Pit), is injected by 0.5U/kg after 10min, and is noted in 5s
Shoot away complete.The ECG Change of rat in 3min is recorded after injection, S-T segment raises >=and 0.1mv is modeling success.
2.5 Rat Ecgs are detected
After injection of pituitrin, record rat occur myocardial ischemia experience time and from ischemic to recover when experience
Time, compare the time difference between intervention group and control group.
2.6 statistical analysis
Experimental data is with mean+SDRepresent, with the software analysis of SPSS 18, compare between multigroup mean
Checked using one-way analysis of variance, P<0.05 be considered as it is statistically significant.
3 results
The weighing observation of 3.1 rat body weights
1st, 3,5 days, there was no significant difference for intervention group and the rat body weight for compareing, and has in the body weight of the 7th day two groups of rats
Difference (such as Fig. 1).
3.2 open energy lamp to the Electrocardiographic impact of the rats with myocardial ischemia that pituitrin is mediated
In the Electrocardiographic waveform of normal rat, T ripples are towering, and after injection of pituitrin, rat cardiac muscle occurs and lacks
After blood, there is the low flat or even inverted phenomenon of T ripples, after rest, presentation is gradually brought to that the trend (figure of front T wave heights is administered
2A)。
Intervention group (Fig. 2 B) compared with control group, after injection of pituitrin, intervention group rat occur myocardial ischemia when
Between be 53.35 ± 15.12s, and control group occur myocardial ischemia time be 23.2 ± 28.71s；Occur continuing after myocardial ischemia
Two groups of recovery situation is observed, is as a result found, the time that intervention group is recovered is 54 ± 25.54s, and the recovery time of control group is then
96.7 ± 37.53s is needed, significant difference is respectively provided with, illustrates to open the rat heart muscle that energy lamp can delay pituitrin to cause
Ischemic, while the recovery of ischemic myocardium can be promoted, reaches the effect of Ischemic myocardium damage.
4 conclusions
Acute Myocardial Ischemia in Rats experiment caused by pituitrin is to study that one of medicaments for resisting myocardial ischemia important and Jing
The animal model of allusion quotation.Acute myocardial ischemia damages cardiac muscle, while with the appearance of abnormal electrocardiographic pattern.ECG ST section, T
Ripple is to react the relatively reliable index of Myocardial injury degree extremely.
The present invention promotes the recovery of ischemic myocardium by suppressing raising for rats with myocardial ischemia ST segment value, reaches the protection heart
The effect of myocardial ischemia.
This result of study shows that open the myocardial ischemia in rats that energy lamp can delay pituitrin to cause, reduction cardiac muscle lacks
Blood is damaged, and shortens the time of myocardial ischemia, illustrates that it has the effect of prevention and treatment myocardial ischemia.
To sum up, opening energy light fixture plays the role of definite treatment and prevention myocardial ischemia, is the treatment of clinical cardiovascular disease
There is provided a kind of new selection, with wide clinical practice and market prospects.
Claims (6)
1. opening can purposes of the lamp in the device for preparing prevention and/or treating myocardial ischemia.
2. purposes according to claim 1, it is characterised in that：Described device is to prevent and/or treat acute myocardial ischemia
Device.
3. purposes according to claim 1, it is characterised in that：Described device is to shorten the device of duration of myocardial ischemia.
4. the purposes according to claims 1 to 3 any one, it is characterised in that：The energy lamp that opens includes that super oxygen can be produced
Anion O2 -Broad band full spectrum frequency spectrograph and ultrasonic humidifier；The broad band full spectrum frequency spectrograph from top to bottom includes earth-free
The cabinet of outer shielding structure, support and base；Metal alloy plate, quartzy carbon pipe are provided with the cabinet；It is described
Quartzy carbon pipe is used to radiate the beneficial visible ray of 500nm～2.5 μm frequency spectrum and near, mid-infrared light；The metal alloy plate is inhaled
Receive infrared from 500nm～2.5 mum wavelength of quartzy carbon pipe, while it is infrared to radiate 2.5 μm～25 mum wavelengths；The support is used
In supporting plastic casing and connection cabinet and base；The metal alloy plate top is by least 10 quartzy carbon pipe series connection
Composition；The ultrasonic humidifier is located at broad band full and composes for producing a large amount of water smokes between frequency spectrograph and human body, and water smoke need to be with frequency
Light quantum generation that spectrometer sends effect, water smoke disappears before frequency spectrograph panel be ultrasonic humidifier and frequency spectrograph it is optimal away from
From.
5. purposes according to claim 4, it is characterised in that：The front of the cabinet is provided with machine shell panel, casing
Panel is provided with panel guard；Micro- shape fan, metal air chamber, metal alloy are respectively equipped with the cabinet by rear to front
Plate, quartzy carbon pipe；The cabinet it is upper, under be respectively provided with double louvres, this pair of louvre is used to guarantee extraneous air micro-
Shape fan is twitched lower into the metal air chamber being fixed on cabinet；Metal air chamber surrounding lower section is equipped with air admission hole, is used for
Air is guaranteed via the infrared metal alloy plate surface space electronic cloud of 2.5 μm～25 mum wavelengths of radiation, absorption negative electrical charge is formed
Superoxide anion, Jing panel guards are communicated in air.
6. purposes according to claim 5, it is characterised in that：The metal alloy plate top is by least 10 quartzy carbons
Pipe is composed in series；The machine shell panel is provided with power switch and quartzy carbon pipe switch；Automatic line receiver is set in the base,
Spooler jump ring, and the anti-dumping switch for automatically powering off when base inclines more than 15 degree of angles.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710124505.2A CN106581870A (en) | 2017-03-03 | 2017-03-03 | Purpose of light-message-transmission-medium energy enablement lamp serving as treatment device for myocardial ischemia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710124505.2A CN106581870A (en) | 2017-03-03 | 2017-03-03 | Purpose of light-message-transmission-medium energy enablement lamp serving as treatment device for myocardial ischemia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN106581870A true CN106581870A (en) | 2017-04-26 |
Family
ID=58587317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710124505.2A Pending CN106581870A (en) | 2017-03-03 | 2017-03-03 | Purpose of light-message-transmission-medium energy enablement lamp serving as treatment device for myocardial ischemia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN106581870A (en) |
Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101122180A (en) * | 2007-09-17 | 2008-02-13 | 张景和 | Tourmaline health preserving room |
| CN101336785A (en) * | 2008-08-13 | 2009-01-07 | 高洪祥 | Far-infrared negative-ion magnetic health mattress |
| CN101496935A (en) * | 2008-01-31 | 2009-08-05 | 易智强 | Physiotherapy equipment with composite efficacy |
| CN102451524B (en) * | 2011-06-29 | 2014-07-23 | 郑国贤 | Physiotherapy instrument and use method thereof |
| TWI446933B (en) * | 2012-12-17 | 2014-08-01 | Jin Hong Chang | Health maintenance material for use of preparing medicine for prevention and cure of cardiovascular diseases and health maintenance of biotechnology |
| CN204293698U (en) * | 2014-11-26 | 2015-04-29 | 彭良玉 | A kind of QI and blood bilateral negative oxygen ion health-care physiotherapeutic room |
| CN205054209U (en) * | 2015-09-23 | 2016-03-02 | 冼添丽 | Multi -functional healthy hand lace |
| CN205108775U (en) * | 2015-11-13 | 2016-03-30 | 王宝光 | Far infrared negative oxygen ion energy room |
| CN105617540A (en) * | 2015-12-25 | 2016-06-01 | 南通生命多奇健康科技有限公司 | Light supplementing health preserving instrument |
-
2017
- 2017-03-03 CN CN201710124505.2A patent/CN106581870A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101122180A (en) * | 2007-09-17 | 2008-02-13 | 张景和 | Tourmaline health preserving room |
| CN101496935A (en) * | 2008-01-31 | 2009-08-05 | 易智强 | Physiotherapy equipment with composite efficacy |
| CN101336785A (en) * | 2008-08-13 | 2009-01-07 | 高洪祥 | Far-infrared negative-ion magnetic health mattress |
| CN102451524B (en) * | 2011-06-29 | 2014-07-23 | 郑国贤 | Physiotherapy instrument and use method thereof |
| TWI446933B (en) * | 2012-12-17 | 2014-08-01 | Jin Hong Chang | Health maintenance material for use of preparing medicine for prevention and cure of cardiovascular diseases and health maintenance of biotechnology |
| CN204293698U (en) * | 2014-11-26 | 2015-04-29 | 彭良玉 | A kind of QI and blood bilateral negative oxygen ion health-care physiotherapeutic room |
| CN205054209U (en) * | 2015-09-23 | 2016-03-02 | 冼添丽 | Multi -functional healthy hand lace |
| CN205108775U (en) * | 2015-11-13 | 2016-03-30 | 王宝光 | Far infrared negative oxygen ion energy room |
| CN105617540A (en) * | 2015-12-25 | 2016-06-01 | 南通生命多奇健康科技有限公司 | Light supplementing health preserving instrument |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wang et al. | Gain with no pain? Pain management in dermatological photodynamic therapy | |
| Rich | Symptom clusters in cancer patients and their relation to EGFR ligand modulation of the circadian axis | |
| WO2010134007A3 (en) | Low-level energy laser therapy | |
| CN104368035B (en) | A kind of biological dressing for eliminating human body hickie and scar | |
| CN106692153A (en) | Compound rhizoma curcumae longae tablet | |
| CN103830412B (en) | A kind of preparation method and application of shiny-leaved yellowhorn total saposins | |
| CN108785357A (en) | A kind of masticinic acid and myrrh terpene compatible composition and its preparation method and application | |
| CN106581870A (en) | Purpose of light-message-transmission-medium energy enablement lamp serving as treatment device for myocardial ischemia | |
| CN1698682A (en) | Chinese traditional medicine composition with effects of activating blood circulation, dissipating blood stasis, relaxing, activating the tendons, reducing swelling and easing pain and preparation met | |
| CN207768585U (en) | A kind of Orthopaedic nursing device | |
| CN209220920U (en) | A kind of fumigator for Chinese medicine | |
| CN207970346U (en) | A kind of medical infrared therapy lamp | |
| Turley et al. | Bilateral thoracoscopic cervical sympathectomy for the treatment of recurrent polymorphic ventricular tachycardia | |
| CN101708190B (en) | Preparation method of wood louse extract and application thereof in antiphlogistic and antalgic medicine | |
| CN205357733U (en) | Theftproof bee ware | |
| CN113768723A (en) | Intelligent ultraviolet treatment cabin for treating senile osteoporosis diseases | |
| CN102526426A (en) | Medicine for treating esophageal cancer | |
| CN109172824A (en) | A kind of pharmaceutical composition and preparation method thereof for treating cutaneous squamous cell carcinoma | |
| CN209490388U (en) | A kind of ear nose larynx therapeutic device | |
| CN206324474U (en) | A kind of deinsectization Chinese medicine cabinet | |
| CN208355936U (en) | A kind of regulating instrument that can prevent, treat altitude response | |
| CN101637634A (en) | Incoherent monochromatic source medical device and applications thereof | |
| CN101361708A (en) | Morphine sulphate suppository and preparation method thereof | |
| CN204840232U (en) | A foot acupuncture point is evaporated and is smoked health care appearance for house endowment | |
| CN209696076U (en) | It is a kind of for treating the microwave neck guard cover of throat disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20170426 |
|
| RJ01 | Rejection of invention patent application after publication |